Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Gilead cystic fibrosis treatment reaches trial goal
The drug reached its primary efficacy endpoint of change at day 28 of the trial from baseline in respiratory symptoms, as assessed by the Cystic Fibrosis Questionnaire-Revised (CFQ-R),
The drug reached its primary efficacy endpoint of change at day 28 of the trial from baseline in respiratory symptoms, as assessed by the Cystic Fibrosis Questionnaire-Revised (CFQ-R),
LymphoStat-B, a human monoclonal antibody, is being developed by Human Genome Sciences (HGS) and GlaxoSmithKline under a definitive development and commercialization agreement entered into in August 2006. The
The $360 million buyout offer includes all of the outstanding shares of Bradley common stock and class B common stock. According to Mr Glassman, the offer price represents
The study, which was conducted under a cooperative R&D agreement, was performed at the National Cancer Institute (NCI) of the National Institutes of Health. In the study, a
The agreement grants Takeda non-exclusive rights to research, develop, manufacture and commercialize antibodies based on the technology for an undisclosed number of targets. In return, BioWa will receive
Rexahn, which specializes in discovering, developing and commercializing treatments for cancer among other diseases, said that enrollment for the phase II trial of Archexin, a first-in-class signal inhibitor,
Although the T790M mutation confers resistance to the inhibitory effects of Tarceva (erlotinib) and Iressa (gefitinib), preclinical data indicate that Exelixis candidate XL647 can potently inhibit this mutation
The jury found that Roche had failed to adequately warn Andrew McCarrell of the drug’s bowel disease risks, and this was a major contributory cause of his illness.
The drug, XMT-1001, is a Fleximer-based prodrug of camptothecin (CPT), a well-characterized topoisomerase I inhibitor with potent anti-tumor activity. The drug utilizes the company’s Fleximer technology which delivers
Apogossypol is a small molecule that is believed to inhibit key prosurvival proteins from the Bcl-2 family. Preclinical models have suggested that the inhibition of these proteins by